GSK
GSK plc
NYSEUSDEQUITY
Healthcare
DELAYED
Sell
-39/100
Last price
46.83
▲ 0.28 (0.60%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
46.36
Prev close
46.55
Day high
47.01
Day low
46.18
Volume
6.81M
Market cap
$93.36B
P/E (TTM)
14.70
52W range
42.85 – 61.70
Day trading desk
Gap from prior close
-0.41%
Prior close 46.55
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
1.01%
46.36 – 46.83
Position in range
100%
Near session high
ATR (14D)
0.89
1.90% of price
Prior day high
46.89
PDH
Prior day low
46.33
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 3.73M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.57%
-7.5%
1M
-6.59%
-7.8%
3M
-11.27%
-15.8%
6M
-16.55%
-34.7%
YTD
-4.98%
-19.2%
1Y
+7.50%
-8.9%
3Y
+28.55%
-53.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GSK open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.22M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 18, 26 | Anderson (Elizabeth McKee) |
BUY | 626 | $31.21K | Direct |
| Sep 18, 26 | Bancroft (Charles A) |
BUY | 1.73K | $86.44K | Direct |
| Sep 18, 26 | Beal (Anne M.D.) |
BUY | 637 | $31.75K | Direct |
| Sep 18, 26 | Dietz (Hal) |
BUY | 768 | $38.28K | Direct |
| Sep 18, 26 | Lee (Jeannie) |
BUY | 653 | $32.55K | Direct |
| Sep 18, 26 | Sikka (Vishal Ph.D.) |
BUY | 994 | $49.55K | Direct |
| Aug 24, 26 | Martinez-Davis (Maya) |
BUY | 9 | $466 | Direct |
| Aug 21, 26 | Martinez-Davis (Maya) |
SELL | 44.40K | $2.32M | Direct |
| Aug 14, 26 | Martinez-Davis (Maya) |
BUY | 83 | $4.11K | Direct |
| Aug 14, 26 | Barron (Hal V) |
BUY | 2.28K | $112.91K | Direct |
| Aug 14, 26 | Barron (Hal V) |
BUY | 73 | $3.61K | Direct |
| Aug 7, 26 | Martinez-Davis (Maya) |
BUY | 9 | $476 | Direct |
| Jul 14, 26 | Martinez-Davis (Maya) |
BUY | 321 | $16.59K | Direct |
| Jul 14, 26 | Ramakrishnan (Shobie) |
BUY | 660 | $34.10K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Anderson (Elizabeth McKee) |
— | 4.90K | Bought |
Bancroft (Charles A) |
— | 45.17K | Bought |
Barron (Hal V) |
— | 604.53K | Bought |
Beal (Anne M.D.) |
— | 5.62K | Bought |
Conrad (D) |
— | 7.57K | Bought |
Dietz (Hal) |
— | 5.54K | Bought |
Dodge & Cox |
— | 56.12M | Decrease |
Goodman (Jesse) |
— | 15.98K | Bought |
Ramakrishnan (Shobie) |
— | 514.76K | Bought |
Sikka (Vishal Ph.D.) |
— | 15.30K | Bought |
Fundamentals
Market cap$93.36B
Enterprise value$108.08B
Revenue (TTM)$33.20B
Gross profit$24.40B
EBITDA$10.82B
Net income$4.82B
EPS (TTM)$3.17
Free cash flow$3.48B
Total cash$3.11B
Total debt$18.29B
Book value / share$11.76
Shares outstanding2.00B
Float1.94B
Short % of float0.73%
Dividend yield3.90%
Beta (5Y)0.28
Valuation & profitability ratios
Trailing P/E14.70
Forward P/E9.43
PEG ratio5.66
Price / sales—
Price / book3.96
EV / revenue3.26
EV / EBITDA9.99
Gross margin73.49%
Operating margin30.94%
Profit margin14.52%
Return on equity33.38%
Return on assets10.01%
Debt / equity106.50
Current ratio0.82
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $32.67B | $31.38B | $30.33B | $29.32B | +4.1% |
| Operating revenue | $32.67B | $31.38B | $30.33B | $29.32B | +4.1% |
| Cost of revenue | $9.02B | $9.05B | $8.56B | $9.55B | -0.3% |
| Gross profit | $23.65B | $22.33B | $21.76B | $19.77B | +5.9% |
| Research & development | $7.53B | $6.40B | $6.22B | $5.49B | +17.6% |
| Selling, general & admin | $9.09B | $11.02B | $9.38B | $8.37B | -17.5% |
| Total operating expense | $15.31B | $16.79B | $14.42B | $13.04B | -8.8% |
| Operating income | $8.34B | $5.54B | $7.34B | $6.73B | +50.5% |
| Net interest income | -$633.00M | -$603.00M | -$735.00M | -$826.00M | -5.0% |
| Pre-tax income | $7.40B | $3.48B | $6.06B | $5.63B | +112.9% |
| Tax provision | $1.11B | $526.00M | $756.00M | $707.00M | +111.4% |
| Net income | $5.72B | $2.58B | $4.93B | $14.96B | +122.0% |
| Net income to common | $5.72B | $2.58B | $4.93B | $14.96B | +122.0% |
| Basic EPS | 2.82 | 1.26 | 2.43 | 7.43 | +123.3% |
| Diluted EPS | 2.78 | 1.24 | 2.40 | 7.32 | +123.2% |
| EBIT | $8.09B | $4.12B | $6.79B | $6.45B | +96.5% |
| EBITDA | $10.40B | $6.67B | $9.08B | $8.60B | +56.0% |
| Basic shares | 2.03B | 2.04B | 2.03B | 2.01B | -0.6% |
| Diluted shares | 2.06B | 2.07B | 2.06B | 2.04B | -0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.15B | $3.69B | $2.75B | $3.52B | -14.7% |
| Cash & short-term investments | $3.16B | $3.71B | $4.99B | $7.68B | -14.9% |
| Accounts receivable | $5.91B | $5.56B | $5.91B | $5.45B | +6.3% |
| Inventory | $5.92B | $5.67B | $5.50B | $5.15B | +4.5% |
| Total current assets | $17.51B | $17.00B | $18.64B | $20.77B | +3.0% |
| Property, plant & equipment | $10.05B | $10.07B | $9.96B | $9.62B | -0.2% |
| Goodwill & intangibles | $23.77B | $22.50B | $21.58B | $21.36B | +5.6% |
| Total assets | $61.12B | $59.46B | $59.01B | $60.15B | +2.8% |
| Total current liabilities | $21.39B | $21.70B | $21.07B | $22.81B | -1.4% |
| Current debt | $2.88B | $2.18B | $2.66B | $3.79B | +31.8% |
| Long-term debt | $14.02B | $13.70B | $14.15B | $16.19B | +2.3% |
| Total debt | $17.72B | $16.99B | $18.02B | $20.99B | +4.3% |
| Total liabilities | $45.16B | $46.38B | $46.21B | $50.05B | -2.6% |
| Retained earnings | $10.21B | $7.80B | $7.24B | $4.36B | +31.0% |
| Shareholder equity | $16.38B | $13.67B | $13.35B | $10.60B | +19.8% |
| Working capital | -$3.88B | -$4.70B | -$2.42B | -$2.04B | +17.4% |
| Net tangible assets | -$7.39B | -$8.83B | -$8.23B | -$10.77B | +16.3% |
| Shares issued | 4.32B | 4.31B | 4.31B | 4.31B | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $6.29B | $2.95B | $5.31B | $4.92B | +113.1% |
| Depreciation & amortisation | $2.31B | $2.55B | $2.29B | $2.15B | -9.3% |
| Stock-based compensation | $374.00M | $344.00M | $307.00M | $346.00M | +8.7% |
| Change in working capital | -$1.44B | $2.09B | -$364.00M | $270.00M | -168.8% |
| Operating cash flow | $7.74B | $6.55B | $6.77B | $7.40B | +18.1% |
| Capital expenditure | -$2.98B | -$2.98B | -$2.34B | -$2.26B | -0.1% |
| Investing cash flow | -$4.23B | -$1.23B | -$1.59B | -$8.77B | -244.4% |
| Share buybacks | -$1.38B | $0 | $0 | — | — |
| Dividends paid | -$2.56B | -$2.44B | -$2.25B | -$3.47B | -4.9% |
| Financing cash flow | -$3.69B | -$4.73B | -$5.64B | $823.00M | +22.0% |
| Free cash flow | $4.76B | $3.57B | $4.42B | $5.14B | +33.1% |
| End cash position | $3.21B | $3.40B | $2.86B | $3.42B | -5.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $8.41B | $7.63B | $8.62B | $8.55B | $7.99B | +10.2% |
| Operating revenue | $8.41B | $7.63B | $8.62B | $8.55B | $7.99B | +10.2% |
| Cost of revenue | $2.27B | $1.88B | $2.66B | $2.26B | $2.17B | +20.9% |
| Gross profit | $6.14B | $5.75B | $5.96B | $6.29B | $5.82B | +6.8% |
| Research & development | $3.47B | $1.69B | $2.35B | $1.69B | $2.02B | +104.8% |
| Selling, general & admin | $2.20B | $2.12B | $2.64B | $2.24B | $2.14B | +3.9% |
| Total operating expense | $5.66B | $3.46B | $4.46B | $3.70B | $3.80B | +63.6% |
| Operating income | $481.00M | $2.29B | $1.51B | $2.59B | $2.02B | -79.0% |
| Net interest income | -$124.00M | -$145.00M | -$250.00M | -$141.00M | -$134.00M | +14.5% |
| Pre-tax income | $354.00M | $2.14B | $950.00M | $2.46B | $1.89B | -83.5% |
| Tax provision | -$199.00M | $305.00M | $223.00M | $312.00M | $241.00M | -165.2% |
| Net income | $435.00M | $1.74B | $636.00M | $2.01B | $1.44B | -75.0% |
| Net income to common | $435.00M | $1.74B | $636.00M | $2.01B | $1.44B | -75.0% |
| Basic EPS | 0.22 | 0.86 | 0.32 | 1.00 | 0.71 | -75.0% |
| Diluted EPS | 0.21 | 0.85 | 0.31 | 0.98 | 0.70 | -74.9% |
| EBIT | $536.00M | $2.31B | $1.12B | $2.62B | $2.07B | -76.8% |
| EBITDA | $2.83B | $2.77B | $1.12B | $3.36B | $3.23B | +1.9% |
| Basic shares | 2.01B | 2.01B | 2.01B | 2.02B | 2.03B | -0.2% |
| Diluted shares | 2.03B | 2.04B | 2.04B | 2.05B | 2.06B | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.10B | $3.44B | $3.15B | $3.30B | $3.60B | -9.8% |
| Cash & short-term investments | $3.11B | $3.44B | $3.16B | $3.31B | $3.62B | -9.8% |
| Accounts receivable | $7.71B | $7.76B | $5.91B | $7.94B | $7.32B | -0.6% |
| Inventory | $6.28B | $6.16B | $5.92B | $6.12B | $6.07B | +2.0% |
| Total current assets | $17.56B | $17.76B | $17.51B | $17.84B | $17.67B | -1.1% |
| Property, plant & equipment | $10.03B | $10.04B | $10.05B | $10.13B | $9.92B | -0.1% |
| Goodwill & intangibles | $24.18B | $25.43B | $23.77B | $23.98B | $22.11B | -4.9% |
| Total assets | $61.74B | $62.87B | $61.12B | $61.34B | $59.26B | -1.8% |
| Total current liabilities | $21.53B | $22.43B | $21.39B | $21.33B | $20.38B | -4.0% |
| Current debt | — | — | $2.88B | — | — | — |
| Long-term debt | — | — | $14.02B | — | — | — |
| Total debt | $18.24B | $19.06B | $17.72B | $17.75B | $17.35B | -4.3% |
| Total liabilities | $44.56B | $45.45B | $45.16B | $45.59B | $44.90B | -1.9% |
| Retained earnings | $11.46B | $11.59B | $10.21B | $10.02B | $8.80B | -1.1% |
| Shareholder equity | $17.64B | $17.85B | $16.38B | $16.15B | $14.79B | -1.2% |
| Working capital | -$3.98B | -$4.67B | -$3.88B | -$3.49B | -$2.71B | +14.8% |
| Net tangible assets | -$6.54B | -$7.57B | -$7.39B | -$7.83B | -$7.32B | +13.7% |
| Shares issued | 4.32B | 4.32B | 4.32B | 4.32B | 4.32B | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $553.00M | $1.84B | $727.00M | $2.14B | $1.65B | -69.9% |
| Depreciation & amortisation | $2.29B | $463.00M | -$406.00M | $738.00M | $1.16B | +394.6% |
| Change in working capital | $560.00M | -$1.08B | $588.00M | -$206.00M | -$1.03B | +151.8% |
| Operating cash flow | $2.69B | $1.14B | $2.28B | $2.22B | $2.10B | +135.8% |
| Capital expenditure | -$653.00M | -$443.00M | -$1.02B | -$879.00M | -$633.00M | -47.4% |
| Investing cash flow | -$789.00M | -$1.47B | -$933.00M | -$1.53B | -$625.00M | +46.2% |
| Share buybacks | -$308.00M | -$326.00M | -$252.00M | -$317.00M | -$561.00M | +5.5% |
| Dividends paid | -$727.00M | -$643.00M | -$646.00M | -$650.00M | -$656.00M | -13.1% |
| Financing cash flow | -$2.15B | $272.00M | -$856.00M | -$1.31B | -$2.37B | -890.1% |
| Free cash flow | $2.04B | $698.00M | $1.25B | $1.34B | $1.46B | +191.8% |
| End cash position | $2.94B | $3.20B | $3.21B | $2.76B | $3.32B | -8.0% |
Options analytics
Put / call volume
0.21
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
43.00
-7.7% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
292
Contracts, this expiry
Put volume
62
Contracts, this expiry
Heaviest call OI
43.00
0 contracts
Heaviest put OI
43.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.25 | 1.34 | +7.2% |
| Mar 2026 | 1.16 | 1.26 | +7.9% |
| Dec 2025 | 0.62 | 0.70 | +11.9% |
| Sep 2025 | 1.26 | 1.46 | +15.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.33 | 2 | $8.86B | +3.7% |
| Next quarter | 0.77 | 2 | $8.98B | +4.2% |
| Current year | 4.76 | 5 | $33.91B | +3.8% |
| Next year | 4.94 | 5 | $35.49B | +4.6% |
Analyst targets & ownership
Mean target$59.45
High target$70.00
Low target$49.00
Implied upside26.95%
Analyst count8
ConsensusHOLD
Strong buy / Buy1 / 2
Hold4
Sell / Strong sell1 / 0
Held by insiders0.06%
Held by institutions17.47%
Institutions holding1.21K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
48.32
-3.08% from price
SMA 20
49.07
-5.04% from price
SMA 50
50.42
-7.57% from price
SMA 100
50.96
-8.11% from price
SMA 200
52.40
-11.06% from price
EMA 12
48.22
-2.89% from price
EMA 26
49.16
-4.75% from price
EMA 50
49.99
-6.31% from price
RSI (14)
32.3
Neutral
MACD (12,26,9)
-0.94
Hist -0.33
ATR (14)
0.89
1.91% of price
Realised vol 30D
22.7%
Annualised
Bollinger upper
51.89
20, 2σ
Bollinger lower
46.26
20, 2σ
50 / 200 cross
Death
50.42 vs 52.40
Trend bias
Below 200
-11.06%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.24
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
22.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-23.9%
Peak to trough
Max drawdown 5Y
-38.8%
Peak to trough
ATR 14
0.89
1.91% of price
Beta (reported)
0.28
5Y monthly, from filing
Short interest
Shares short
14.65M
Prior 14.78M
Change vs prior
-0.9%
Shorts covering
% of float
0.73%
Normal
% of shares out
0.73%
Against total outstanding
Days to cover
5.3
Crowded exit
Float
1.94B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 6, 26 | Barclays | DOWNGRADE | Equal-Weight | Underweight |
| Nov 12, 24 | Jefferies | DOWNGRADE | Buy | Hold |
| Oct 31, 24 | Guggenheim | DOWNGRADE | Buy | Neutral |
| Jul 8, 24 | UBS | DOWNGRADE | Buy | Neutral |
| Jul 2, 24 | Jefferies | MAINTAINED | Buy | Buy |
| May 30, 24 | Goldman Sachs | INITIATED | — | Neutral |
| Mar 4, 24 | Guggenheim | UPGRADE | Neutral | Buy |
| Jan 23, 24 | Morgan Stanley | INITIATED | — | Equal-Weight |
| Jan 3, 24 | Jefferies | UPGRADE | Hold | Buy |
Dividends & splits
Forward rate$1.82 / yr
Forward yield3.90%
5-year avg yield4.12%
Payout ratio56.55%
Ex-dividend dateAug 14, 2026
Next pay dateOct 8, 2026
Last split1226:1000
Split dateJul 22, 2022
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-10-01
Corporate Changes & Voting Matters
6-K · 2026-09-24
Corporate Changes & Voting Matters
6-K · 2026-09-22
Corporate Changes & Voting Matters
6-K · 2026-09-15
Corporate Changes & Voting Matters
6-K · 2026-09-14
Corporate Changes & Voting Matters
6-K · 2026-09-11
Corporate Changes & Voting Matters
6-K · 2026-09-10
Corporate Changes & Voting Matters
6-K · 2026-09-09
Headlines
ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia
Business Wire · 20h ago
Cerebras Systems’ Tough 2026 Continues: It’ll Double Soon According to One of The Biggest Global Banks
24/7 Wall St. · 2d ago
Abbott Stock And Other Healthcare Dividend Names Built For Supply Chain Shocks
Simply Wall St. · 6d ago
GSK (LSE:GSK) The Latest Update Raises A Bigger Question
Simply Wall St. · 7d ago
Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies
GlobeNewswire · 7d ago
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?
Zacks · 8d ago
GSK retains ‘buy’ rating at Jefferies as B7H3 cancer programme seen as underappreciated
Proactive · 8d ago
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
Zacks · 9d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.